Milestone Scientific (MLSS) Q1 2025 earnings summary

Executive summary

• Revenue for Q1 2025 was $2.23 million, down slightly from $2.25 million in Q1 2024, with dental segment sales stable and medical segment sales increasing year-over-year.

• Gross profit decreased to $1.65 million from $1.68 million year-over-year, with gross margin remaining strong.

• Net loss widened to $2.0 million from $1.4 million in the prior year quarter, driven by higher operating expenses and increased R&D investment.

• The company continues to focus on expanding its dental and medical device businesses, leveraging its proprietary DPS Dynamic Pressure Sensing technology.

Financial highlights

• Product sales: $2.23 million in Q1 2025 vs. $2.25 million in Q1 2024; dental sales $2.18 million, medical sales $51,000.

• Gross profit: $1.65 million in Q1 2025 vs. $1.68 million in Q1 2024; gross margin stable.

• Operating expenses increased to $3.65 million from $3.14 million, mainly due to higher R&D and professional fees.

• Net loss: $2.0 million in Q1 2025 vs. $1.4 million in Q1 2024; EPS remained at $(0.02).

• Cash and cash equivalents at quarter-end: $2.2 million, with working capital of $4.2 million.

Outlook and guidance

• Management is implementing plans to increase revenue and reduce professional and consulting fees over the next twelve months.

• Research and development on the next-generation Single Tooth Anesthesia System has been delayed to conserve cash.

• $800,000 in related party note financing received in April 2025 is expected to support operations for the next twelve months.